Jul 2026· Cell Death and Disease· Vol 17· 0 citations· 28 references
Medicine
TL;DR
It is demonstrated that perturbation of the ERK-MyD88 complex rewires cellular signaling into cell-autonomous hubs that coordinate caspase activation with chemokine secretion, thereby driving a program of immunogenic cancer cell death.
Abstract
The RAS-MAPK pathway is frequently dysregulated in cancer, leading to malignant transformation. We previously identified a direct interaction between MyD88, a central adaptor of inflammatory signaling, and ERK, the terminal kinase of the RAS-MAPK cascade. Pharmacologic disruption of this ERK-MyD88 complex with a small molecule induces immunogenic cell death and antitumor immunity, suggesting a novel therapeutic strategy. Here, we show that ERK-MyD88 inhibition drives cellular signaling from non-canonical hubs. First, ERK-MyD88 disruption activates an integrated stress response that drives caspase-8-dependent apoptosis through a FADD-independent pathway within p62-ubiquitin aggregates. Second, it promotes assembly of MyD88, IRAK1, and IRAK4 into Myddosomes that produce proinflammatory chemokines independently of TLR or IL-1R activation. These findings demonstrate that perturbation of the ERK-MyD88 complex rewires cellular signaling into cell-autonomous hubs that coordinate caspase activation with chemokine secretion, thereby driving a program of immunogenic cancer cell death.
Protein phosphorylation is a fundamental mechanism regulating signal transduction, metabolic control, and cellular adaptation to environmental stress, with these processes orchestrated largely by protein kinases organized into hierarchical signaling cascades. Among these, the p38 mitogen-activated protein kinases (MAPK...
Fredejah T. Royer, Lillian Schulz, Abby E. Young et al.· Biochemical Journal· 0 citations
The TLR4/MyD88 signaling axis serves as a central hub linking microbial- and damage-associated molecular patterns to oncogenic inflammation. Upon ligand engagement, MyD88 orchestrates two major downstream branches, including the canonical NF-κB pathway, which drives transcriptional programs for cell survival, prolifera...
Davood Zaeifi, K. Jamialahmadi, G. Karimi· Pharmacological Research· 0 citations
Fibroblast growth factor receptor (FGFR) signaling is a major oncogenic pathway in multiple cancer types and an important determinant of therapeutic response and resistance. However, its role in coordinating apoptotic susceptibility with tumor immune escape remains insufficiently integrated. This review summarizes how...
Yi-Nan Hu, Xin-Miao Zhang, Wen Liu et al.· Frontiers in Immunology· 0 citations
Glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) is traditionally known as a secreted enzyme that sheds glycosylphosphatidylinositol (GPI)-anchored proteins. Emerging evidence suggests its involvement in immune modulation. In this study, we report a non-canonical intracellular function of GPLD1 in potenti...
Qian Zhao, Renxia Zhang, Yukang Yuan et al.· International Journal of Bio...· 0 citations
Experimental results from breast, lung, gastric, liver, hematological, and melanoma models suggest that dysregulated PDK1 signaling can increase the output of the PI3K-AKT-mTOR pathway, invasion, metabolic adaptation, and resistance to specific hormonal, chemotherapeutic, and targeted therapies.
Darshana Ballagere Honnasiddappa, M. Ramar, Tincy Biju et al.· International Journal of Bio...· 0 citations
Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...
Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al.· Cellular Signalling· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
